Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MDCX

Medicus Pharma Ltd

Apr 01 • 04:00PM ET

3.96

Dollar change +0.24
Percentage change 6.45	%

Healthcare • Biotechnology • Canada • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	77.42%	Shs Outstand	11.82M	Perf Week	23.36%
Market Cap	46.81M	Forward P/E	-	EPS next Y	-1.53	Insider Trans	0.00%	Shs Float	2.67M	Perf Month	4.21%
Income	-11.16M	PEG	-	EPS next Q	-	Inst Own	12.72%	Short Float	2.79%	Perf Quarter	39.44%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	1.51	Perf Half Y	-
Book/sh	0.27	P/B	14.93	EPS next Y	-	ROA	-295.90%	Short Interest	0.07M	Perf Year	-
Cash/sh	0.35	P/C	11.25	EPS next 5Y	19.09%	ROE	-525.44%	52W Range	1.80 - 6.00	Perf YTD	62.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-333.93%	52W High	-34.00%	Beta	-
Dividend TTM	-	Quick Ratio	2.33	Sales past 5Y	0.00%	Gross Margin	-	52W Low	120.00%	ATR (14)	0.50
Dividend Ex-Date	-	Current Ratio	2.33	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	60.06	Volatility	15.45% 18.96%
Employees	12	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	11.00
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	38.85%	Payout	-	Rel Volume	1.91	Prev Close	3.72
Sales Surprise	-	EPS Surprise	-27.07%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	49.22K	Price	3.96
SMA20	21.75%	SMA50	22.19%	SMA200	24.70%	Trades		Volume	93,966	Change	6.45%

Mar-10-25 04:05PM	Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering (Newsfile) +11.48% -23.24%
Mar-06-25 08:30PM	Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering (Newsfile)
07:30AM	Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile)
Feb-27-25 07:30AM	Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (GlobeNewswire) +12.16%
Feb-14-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (GlobeNewswire) +19.48%
07:41AM	Loading…
Feb-11-25 07:41AM	Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV) (Newsfile)
Dec-12-24 07:30AM	Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch (GlobeNewswire)
Dec-02-24 07:30AM	Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region (GlobeNewswire) -8.72%
Nov-18-24 07:30AM	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer (Newsfile) -6.70%
Nov-15-24 04:47PM	Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States (Newsfile) -15.47%

Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. It focuses on identifying, acquiring, and advancing relatively de-risked clinical stage assets through clinical development and commercialization. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDCX

Medicus Pharma Ltd

Upgrade your FINVIZ experience